Merck & Co to create a separate cancer unit as patent cliff looms

Merck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-growing medicines as the blockbuster cancer therapy Keytruda nears patent expiration. The company plans to emphasize newer products, including a pneumonia vaccine and a treatment for lung disease, as key drivers of its next growth phase.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GvSQanm
via IFTTT

Read More

Drug regulator cracks down hard on non-compliant cough syrup makers

Authorities are cracking down on hundreds of cough syrup manufacturers failing quality checks. This action follows tragic deaths linked to toxic ingredients. Inspections are ongoing, with strict measures like unit closures and license cancellations being implemented. The drug regulator aims to eliminate substandard cough syrup production. Manufacturers must adhere to new quality standards or face closure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFP34rK
via IFTTT

Read More

Government urges pharma sector to anchor global supply chains via quality, innovation

Union Minister J P Nadda urged India's pharmaceutical industry to lead global supply chains with quality and innovation. India is embracing new technologies for disease detection and diagnostics. Initiatives like Biopharma Shakti and PRIP are boosting manufacturing and research. The nation is committed to regulatory excellence and aligning with global standards. A quality-first approach is key to sustained global competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Zd4mrz
via IFTTT

Read More

India's drug regulator inspected 90% of cough syrup makers, found lapses, official says

India’s pharmaceutical regulator has launched a thorough inspection of cough syrup manufacturers, discovering several discrepancies in their operating procedures. This decisive action follows alarming reports of child deaths linked to these syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GxY9vwT
via IFTTT

Read More

Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV Prasad

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimilars, anticipating significant growth within five years. Generics and active pharmaceutical ingredients will continue to be major revenue sources. Dr Reddy's aims to compete in a biologics-led future by investing in research and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vAW1EzD
via IFTTT

Read More

Expects Pen-G production capacity to touch 10k metric tonnes in 12 months: Aurobindo Pharma

Aurobindo Pharma is set to boost Penicillin-G output to over 10,000 metric tonnes annually. Its China manufacturing facility is projected to reach EBITDA break-even this quarter. The company is also advancing its US operations and developing complex generics. These strategic moves aim for sustainable growth and improved profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sdLF4H2
via IFTTT

Read More

BahiaFarma, Biocon, Bionovis inks MoU in pharma sector

India and Brazil signed multiple Memoranda of Understanding (MoUs) during Brazilian President Lula da Silva's visit. Key agreements include a pact for developing a breast cancer medicine, cooperation in iron ore blending at Gangavaram Port, and R&D in strategic pharmaceutical ingredients. ApexBrasil and FICCI also agreed to boost trade and investment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PnhsZ48
via IFTTT

Read More